Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, PARP inhibition in cancer therapy, and Cancer Genomics and Diagnostics.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.
Clinical Trial Metrics: The Complexity of Conducting Clinical Trials in North American Cancer Centers
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy
First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors
LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT?
Lymphovascular Invasion in Endometrial Cancer
Too many women are dying from cervix cancer: Problems and solutions
Pancreatic cancer as a sentinel for hereditary cancer predisposition
Long-term Cardiovascular Outcomes Among Endometrial Cancer Survivors in a Large, Population-Based Cohort Study
Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
Combating subclonal evolution of resistant cancer phenotypes
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma
The Addition of Adjuvant Chemotherapy to Radiation in Early-Stage High-Risk Endometrial Cancer